A drug that inhibits 2 enzymes known to help support the growth and survival of malignant B cells has received FDA approval to treat certain adults with forms of leukemia and lymphoma.
Duvelisib, which is marketed as Copiktra, is an oral inhibitor of phosphoinositide 3-kinase (PI3K) and the first approved dual inhibitor of PI3K δ and PI3K γ. It is indicated for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least 2 prior therapies. The drug also received accelerated approval—earlier clearance for medications that treat serious conditions and fill an unmet medical need based on a surrogate end point—for adults with refractory or relapsed follicular lymphoma (FL) after at least 2 previous systemic therapies.
Voelker R. New Treatment for Certain Types of Leukemia and Lymphoma. JAMA. 2018;320(17):1746. doi:10.1001/jama.2018.16523
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: